| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | Wednesday, May 10, 2017 Quintiles and IMS Health came together last year in a massive $19 billion megamerger, and now INC and inVentiv are looking to follow suit, combining into one new major company that will, according to the pair, make it the second largest biopharmaceutical outsourcing provider in the world. |
|
|
Top Stories Of The Week | Wednesday, May 10, 2017 Roche’s Tecentriq wasn’t supposed to fail its phase 3 trial in second-line bladder cancer. But that’s what it just did—and the data shortfall not only endangers the drug’s conditional FDA approval, but could augur trouble ahead for other checkpoint inhibitors that followed Tecentriq into the field. |
|
|
| Monday, May 8, 2017 Kite Pharma was off by 15% in morning trading after it announced the death of a patient in late April of cerebral edema—the very same fatal outcome that beset rival Juno’s Rocket trial, killing five people and its CAR-T program for JCAR015. |
|
|
| Tuesday, May 9, 2017 Not a week seems to go by without a CRO sale rumor: Chiltern, INC Research and PPD (which in fact was recapitalized last week) are two of the most recent, and now the Wall Street Journal is adding Parexel to that list. |
|
|
| Monday, May 8, 2017 Last year, the FDA called for stronger heart-failure warnings on the label of AstraZeneca Type 2 diabetes med Onglyza. And now, AstraZeneca and former partner Bristol-Myers Squibb are being hit with 14 lawsuits related to the med’s heart-failure risks. |
|
|
| Friday, May 5, 2017 Seattle Genetics has terminated a major drug tie-up with Immunomedics after intense legal battles, as Immunomedics revealed that it has axed its president and CEO Cynthia Sullivan. |
|
|
| Monday, May 8, 2017 Sanofi and Regeneron’s new atopic dermatitis drug Dupixent is off to the kind of start drugmakers aim for, judging by the number of prescriptions written so far. And that has analysts hiking their global sales estimates for 2017, with some surpassing $300 million. |
|
|
| Wednesday, May 10, 2017 Though naming experts might be among our readers, our readers aren’t all naming experts. You are, however, a creative bunch. For our Valeant renaming poll, we had to set aside plenty of witticisms, insults and suggestions semiserious to serious to come up with our shortlist of six. Voting's open through Sunday. |
|
|
| Monday, May 8, 2017 Abbott announced the CE mark and launch of its smartphone-compatible insertable cardiac monitor, designed to help physicians remotely diagnose arrhythmias, such as atrial fibrillation, and guide their therapy decisions. |
|
|
| Tuesday, May 9, 2017 A number of companies have tried to keep FDA inspectors from getting a thorough look through their manufacturing plants, but none have gone to the extraordinary lengths of the Vikshara Trading & Investments plant in Gujarat, India, whose products the FDA banned over the deceptions. |
|
|
| Thursday, May 11, 2017 Harvard professor Timothy Springer has always been interested in developing antibodies targeting proteins that are “extracellular”—meaning they reside in bodily fluids, outside of cell walls. But he found that funding was lacking. So he created the Institute for Protein Innovation, which launched in Boston today. He spoke to FierceBiotechResearch about the new institute. |
|
|
| Tuesday, May 9, 2017 Takeda’s plan to launch a Haemophilus influenzae type B vaccine in Japan has ended in smoke as manufacturer GlaxoSmithKline has terminated production of Vaxem Hib. |
|
|
Resources Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. |
